|
Patent landscape, scope, and claims summary: |
US Patent 11,167,004 claims and US patent landscape: what is protected, where it expires, and where generic or biosimilar risk concentrates
Executive summary
US Patent 11,167,004 is a US utility patent with enforceable claims tied to the invention as drafted in its claim set. A full, claim-by-claim analysis and a complete US landscape require the actual claim text and the patent’s bibliographic data (title/assignee/inventors, priority, filing dates, and family members), because claim scope, expiration, and infringement risk vary materially across continuation practice, claim dependencies, and terminal disclaimers. No claim text or patent bibliographic details were provided, so a complete and accurate analysis cannot be produced.
What does US Patent 11,167,004 claim and how broad are its protection boundaries?
Without the claim text, the following cannot be determined in a way that supports licensing, freedom-to-operate, or litigation risk analysis:
- Whether the claims are directed to a product, composition, method of use, manufacturing method, or system/apparatus.
- The independent claim scope (e.g., genus vs species coverage, functional vs structural limitations).
- The presence of active ingredient / dosage form / formulation limitations that map to Orange Book-listed products or NDA/BLA drug codes.
- Whether the claims include therapeutic step sequences, patient selection criteria, parameters (dose ranges, times, temperatures, mixing orders), or diagnostic criteria.
- Claim dependencies that narrow or enlarge the practical infringement perimeter.
What claim types usually drive enforceability in US 11,167,004?
- If method-of-use, infringement hinges on prescribing/inducing and evidentiary link to clinical practice.
- If formulation/product, infringement hinges on composition comparisons and manufacturing traceability.
- If process claims, infringement hinges on unit operations and process parameter matches.
Which patents are in the same family as US Patent 11,167,004 and when do they expire?
A real expiration map requires:
- The earliest effective priority date.
- The filing date for US 11,167,004 and any continuations.
- Whether any claims are subject to terminal disclaimers and how they align with the statutory expiration term.
- Whether related claims exist in sibling US applications that may extend enforceability.
Without these, no accurate expiry timeline can be stated.
How to build an enforceability timeline for this patent estate?
A complete timeline normally includes:
- US statutory term: 20 years from earliest nonprovisional priority subject to filing rules.
- Terminal disclaimer alignment with the parent.
- Any patent term adjustment/offsets.
- Out-of-family differences: if foreign priorities exist, the US term is pegged to the earliest US-valid priority.
How strong is the patent estate for US 11,167,004 based on claim scope and typical litigation posture?
Strength depends on claim construction risk and invalidity posture, which must be anchored to the actual claim language:
- Whether the claims recite specific structural features or only functional outcomes.
- Whether claim terms invite broad indefiniteness or enablement challenges.
- Whether the claims are narrow enough to avoid prior art but broad enough to cover likely competitors.
- Whether the specification supports the full range of claim breadth.
Without claim text, this cannot be done.
What formulations or dosage forms does US Patent 11,167,004 protect?
A formulation landscape requires:
- Claim limitations identifying composition components (polymers, excipients, solvents, salts, particles), release mechanisms (IR/ER), or device integration.
- The drug product context (active ingredient and route).
No such mapping is possible without claim text.
What method-of-use steps does US Patent 11,167,004 cover and which patient populations could be implicated?
Method-of-use claim breadth is determined by:
- Step order, monitoring criteria, and parameter ranges.
- Indications and contraindications.
- Whether the claim is “directed to” a specific therapeutic context.
No claim text means no defensible mapping.
How many US patents cover the same invention as 11,167,004, and which assignees control the overlaps?
Counting overlaps requires:
- Searching US continuation/joint inventor filings tied to the same priority.
- Identifying continuation/divisional families and any separate but related inventions.
- Determining assignment/ownership at filing and current status.
No bibliographic data was provided, so no landscape can be computed.
What Orange Book status exists that could link US 11,167,004 to an NDA or ANDA risk?
Orange Book mapping requires:
- The covered drug product(s) and whether any claims correspond to active ingredient + dosage form + strength or use listed.
- Claim text that matches Orange Book listing rules (including method-of-use listings in some contexts).
Without claim text and without the associated active ingredient, no Orange Book mapping can be produced.
What generic entry risks exist for the product potentially covered by US 11,167,004?
A generic risk analysis requires:
- Identification of the reference listed drug and whether the patent is listed in the Orange Book (and the listed use).
- Whether Paragraph IV filings have been made against the listed patent(s).
- Whether the patent appears in litigation dockets with active brands.
No patent-to-product linkage can be established from the information provided.
How does US Patent 11,167,004 compare with competing patents targeting the same technology?
Comparison requires:
- The invention’s technical core as expressed in the claims.
- The relevant competitors’ claim language in their published applications/patents.
- The ability to perform side-by-side claim charting.
No claim text means no technical core can be extracted.
What patent litigation affects US Patent 11,167,004 and what settlements shape licensing outcomes?
To analyze litigation impacts, the following are required:
- Parties, case numbers, venue, asserted claim numbers, and outcomes.
- Whether the patent was asserted in DA/MDL or direct ANDA litigation.
- Whether settlements include entry triggers, design-arounds, or license scopes.
No litigation identifiers or asserted claims were provided, so the analysis cannot be completed.
When does US Patent 11,167,004 lose exclusivity?
Loss of exclusivity depends on:
- Patent expiration date.
- Whether pediatric extensions apply.
- Whether the patent is listed for Orange Book exclusivity categories (which are narrower than simply “patent ends”).
- Whether regulatory exclusivity (NCE, orphan, 5-year, 7-year, BLA/Biosimilar exclusivities) controls generic timing.
A correct date cannot be generated without bibliographic priority/filing data and the tied product context.
Key Takeaways
- A comprehensive, critical analysis of US Patent 11,167,004 requires the exact claim text and patent bibliographic data (at minimum: title/assignee, earliest priority, filing dates, and family/terminal disclaimer context).
- Without those inputs, any claim-scope, infringement perimeter, expiration timeline, Orange Book mapping, or litigation/Paragraph IV assessment would be unreliable.
FAQs
- How can claim dependencies change infringement risk for a US utility patent?
- What information is needed to map a US patent to Orange Book listings and FDA regulatory timing?
- How do terminal disclaimers alter effective expiration dates for related US patents?
- What evidence is typically required to prove method-of-use infringement in ANDA or Hatch-Waxman contexts?
- How does a claim construction that narrows functional language affect both validity and infringement?
References
- (No sources were provided or identifiable from the request text.)
More… ↓
⤷ Start Trial
|
